To:  ALL PRINCIPAL INVESTIGATORS/NURSES/DATA MANAGERS

 

From: PROTOCOL SECTION

 

Date: JUNE 14, 2019

 

RE: NRG-GY012 REMINDER OF IMPENDING CLOSURE

PROTOCOL TITLE: A Randomized Phase II Study comparing Single-Agent Olaparib, Single-Agent Cediranib and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
NCI Version Date 04/18/2019

Please be aware that NRG-GY012 has accrued 115 of the targeted 120 patient goal. The accrual rate for this trial has been faster than anticipated.  Accrual is expected to be met at any time. Please monitor accrual on the CTSU before approaching a patient. A Closure Notice will be broadcast in the very near future and likely to be effective on or before June 21, 2019.

 

 



Twitter

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address